Promising Signs for MAIA’s Novel Lung Cancer Treatment

Promising Signs for MAIA's Novel Lung Cancer Treatment

by John Conrad| Sep 19, 2024| Member News

MAIA Biotechnology (NYSE American: MAIA) has announced encouraging interim survival data for its lead clinical candidate, THIO, in the treatment of advanced non-small cell lung cancer (NSCLC). The Chicago-based biopharmaceutical company is developing THIO as a targeted immunotherapy for cancer patients who have failed multiple standard treatment regimens.

Key highlights from the Phase II THIO-101 trial include:

• 16 patients surpassed 12-month survival follow-up
• Median survival follow-up in third-line treatment was 10.6 months
• THIO's survival benefit in third-line treatment surpasses the comparable standard-of-care overall survival of 5.8 months
• Treatment with THIO followed by Regeneron's Libtayo® (cemiplimab) has been generally well-tolerated

Dr. Vlad Vitoc, CEO of MAIA Biotechnology, expressed optimism about the results, stating, "THIO is showing a survival benefit for patients with advanced NSCLC. As our follow-up continues, we have noted that three of the earliest patients enrolled are approaching 17-month survival."

The company expects to release full efficacy results of the THIO-101 trial later this year. These promising interim results suggest that THIO, a telomere-targeting agent, could potentially become a valuable treatment option for patients with advanced NSCLC who have exhausted other therapy options.

Investors and patients alike will be eagerly awaiting the complete data set to fully assess THIO's potential in addressing this challenging form of cancer.

Read the press release on Business Wire